Literature DB >> 12853620

Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.

Paola B Arimondo1, Stéphane Angenault, Ludovic Halby, Alexandre Boutorine, Frédéric Schmidt, Claude Monneret, Thérèse Garestier, Jian-Sheng Sun, Christian Bailly, Claude Hélène.   

Abstract

Triple helix-forming oligonucleotides covalently linked to topoisomerase I inhibitors, in particular the antitumor agent camptothecin, trigger topoisomerase I-mediated DNA cleavage selectively in the proximity of the binding site of the oligonucleotide vector. In the present study, we have performed a systematic analysis of the DNA cleavage efficiency as a function of the positioning of the camptothecin derivative, either on the 3' or the 5' side of the triplex, and the location of the cleavage site. A previously identified cleavage site was inserted at different positions within two triplex site-containing 59 bp duplexes. Sequence-specific DNA cleavage by topoisomerase I occurs only with triplex conjugates bearing the inhibitor at the 3'-end of the oligonucleotide and on the oligopyrimidine strand of the duplex. The lack of targeted cleavage on the 5' side is attributed to the structural differences of the 3' and 5' duplex-triplex DNA junctions. The changes induced in the double helix by the triple-helical structure interfere with the action of the enzyme according to a preferred spatial organization. Camptothecin conjugates of oligonucleotides provide efficient tools to probe the organization of the topoisomerase I-DNA complex and will be useful to understand the functioning of topoisomerase I in living cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853620      PMCID: PMC165972          DOI: 10.1093/nar/gkg457

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  31 in total

Review 1.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Eukaryotic topoisomerase I-DNA interaction is stabilized by helix curvature.

Authors:  S Krogh; U H Mortensen; O Westergaard; B J Bonven
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

4.  Minimal DNA duplex requirements for topoisomerase I-mediated cleavage in vitro.

Authors:  J Q Svejstrup; K Christiansen; A H Andersen; K Lund; O Westergaard
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

5.  A model for the mechanism of human topoisomerase I.

Authors:  L Stewart; M R Redinbo; X Qiu; W G Hol; J J Champoux
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

6.  Interactions between eukaryotic DNA topoisomerase I and a specific binding sequence.

Authors:  T Stevnsner; U H Mortensen; O Westergaard; B J Bonven
Journal:  J Biol Chem       Date:  1989-06-15       Impact factor: 5.157

7.  Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.

Authors:  P B Arimondo; C Bailly; A Boutorine; J S Sun; T Garestier; C Hélène
Journal:  C R Acad Sci III       Date:  1999-09

8.  Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.

Authors:  Gary S Laco; Jack R Collins; Brian T Luke; Heiko Kroth; Jane M Sayer; Donald M Jerina; Yves Pommier
Journal:  Biochemistry       Date:  2002-02-05       Impact factor: 3.162

9.  A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.

Authors:  J E Kerrigan; D S Pilch
Journal:  Biochemistry       Date:  2001-08-21       Impact factor: 3.162

10.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.

Authors:  Y Fan; J N Weinstein; K W Kohn; L M Shi; Y Pommier
Journal:  J Med Chem       Date:  1998-06-18       Impact factor: 7.446

View more
  5 in total

1.  Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.

Authors:  Paola B Arimondo; Craig J Thomas; Kahina Oussedik; Brigitte Baldeyrou; Christine Mahieu; Ludovic Halby; Dominique Guianvarc'h; Amélie Lansiaux; Sidney M Hecht; Christian Bailly; Carine Giovannangeli
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

2.  Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures.

Authors:  Smitha Antony; Paola B Arimondo; Jian-Sheng Sun; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2004-10-04       Impact factor: 16.971

3.  Developing a programmed restriction endonuclease for highly specific DNA cleavage.

Authors:  Kristin Eisenschmidt; Thomas Lanio; András Simoncsits; Albert Jeltsch; Vera Pingoud; Wolfgang Wende; Alfred Pingoud
Journal:  Nucleic Acids Res       Date:  2005-12-14       Impact factor: 16.971

4.  Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides.

Authors:  Maria Duca; Dominique Guianvarc'h; Kahina Oussedik; Ludovic Halby; Anna Garbesi; Daniel Dauzonne; Claude Monneret; Neil Osheroff; Carine Giovannangeli; Paola B Arimondo
Journal:  Nucleic Acids Res       Date:  2006-04-05       Impact factor: 16.971

Review 5.  Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?

Authors:  Ben D Bax; Dmitry Sutormin; Neil Q McDonald; Glenn A Burley; Tatyana Shelkovnikova
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.